CN117482144A - 一种治疗妇科疾病的栓剂及其制备方法 - Google Patents
一种治疗妇科疾病的栓剂及其制备方法 Download PDFInfo
- Publication number
- CN117482144A CN117482144A CN202311741727.0A CN202311741727A CN117482144A CN 117482144 A CN117482144 A CN 117482144A CN 202311741727 A CN202311741727 A CN 202311741727A CN 117482144 A CN117482144 A CN 117482144A
- Authority
- CN
- China
- Prior art keywords
- suppository
- group
- fine powder
- fructus cnidii
- boric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000829 suppository Substances 0.000 title claims abstract description 97
- 238000002360 preparation method Methods 0.000 title abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 58
- 239000003814 drug Substances 0.000 claims abstract description 31
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 23
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 23
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000004327 boric acid Substances 0.000 claims abstract description 23
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 17
- 229940037003 alum Drugs 0.000 claims abstract description 17
- 229940041616 menthol Drugs 0.000 claims abstract description 17
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229940116229 borneol Drugs 0.000 claims abstract description 16
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 16
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 16
- 244000223014 Syzygium aromaticum Species 0.000 claims abstract description 12
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 208000008350 Pruritus Vulvae Diseases 0.000 claims abstract description 6
- 241000224526 Trichomonas Species 0.000 claims abstract description 6
- 206010056530 Vulvovaginal pruritus Diseases 0.000 claims abstract description 6
- 230000008961 swelling Effects 0.000 claims abstract description 6
- 208000002003 vulvitis Diseases 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 21
- 238000001914 filtration Methods 0.000 claims description 14
- 238000000227 grinding Methods 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 14
- 238000007873 sieving Methods 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 125000005456 glyceride group Chemical group 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 238000002844 melting Methods 0.000 claims description 7
- 230000008018 melting Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 244000293323 Cosmos caudatus Species 0.000 claims description 6
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 6
- 208000004926 Bacterial Vaginosis Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 208000003251 Pruritus Diseases 0.000 abstract description 12
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 11
- 241000894006 Bacteria Species 0.000 abstract description 6
- 206010046914 Vaginal infection Diseases 0.000 abstract description 6
- 230000007803 itching Effects 0.000 abstract description 6
- 238000012360 testing method Methods 0.000 abstract description 6
- 206010042674 Swelling Diseases 0.000 abstract description 5
- 208000028659 discharge Diseases 0.000 abstract description 5
- 244000045947 parasite Species 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 229960002645 boric acid Drugs 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 17
- 241000700159 Rattus Species 0.000 description 10
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 9
- 210000001215 vagina Anatomy 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- 210000000683 abdominal cavity Anatomy 0.000 description 7
- 230000004089 microcirculation Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 229920002307 Dextran Polymers 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 240000003085 Quassia amara Species 0.000 description 6
- 235000009694 Quassia amara Nutrition 0.000 description 6
- 230000007794 irritation Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000004400 mucous membrane Anatomy 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 208000000114 Pain Threshold Diseases 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000037040 pain threshold Effects 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 4
- 229940013788 quassia Drugs 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000001139 anti-pruritic effect Effects 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 240000000950 Hippophae rhamnoides Species 0.000 description 2
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- 240000004659 Picrasma quassioides Species 0.000 description 2
- 235000010913 Picrasma quassioides Nutrition 0.000 description 2
- 235000011984 Simarouba amara Nutrition 0.000 description 2
- 235000009689 Simarouba glauca Nutrition 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Marine Sciences & Fisheries (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种治疗妇科疾病的栓剂及其制备方法,该中药组合物是由苦参、蛇床子、白鲜皮、丁香叶、珍珠层粉、枯矾、薄荷脑、冰片、硼酸共九味中药制备而成;该药具有清热解毒、燥湿止带、杀虫止痒的功效;主要用于治疗湿热下注、带脉失约、赤白带下、阴痒阴肿,以及滴虫、霉菌、细菌引起的阴道炎、外阴炎等;用途是在治疗湿热下注、带脉失约、赤白带下、阴痒阴肿,以及滴虫、霉菌、细菌引起的阴道炎、外阴炎等药物中的应用;其临床药效学试验效果显著,生物利用度高,且无任何毒副作用。
Description
技术领域
本发明涉及一种治疗妇科疾病的栓剂及其制备方法,属于制药技术领域。
技术背景
妇炎平栓主要治疗湿热下注所致的带下病、阴道炎,症见带脉失约、赤白带下、阴痒阴肿,以及滴虫、霉菌、细菌引起的阴道炎、外阴炎等。现有技术检索:1、中国专利公报2005年1月5日公开了名称为“妇炎平栓及制备方法”公开号为CN1559577A的专利申请,此发明原料药的组成为:苦参500g、珍珠层粉5g、盐酸小檗碱40g、苦木400g、冰片10g、硼酸60g、蛇床子400g、薄荷脑4g、枯矾100g。2、中国专利公报2009年6月17日公开了名称为“一种用于治疗妇科疾病的栓剂及其制备方法”公开号为CN101455715A的专利申请,此发明原料药的组成为:苦参500g、珍珠层粉5g、枯矾100g、苦木400g、蛇床子400g、盐酸小檗碱40g、薄荷脑4g、冰片10g、硼酸60g、沙棘籽油250ml。发明人经多年研究发现:以上现有技术1CN1559577A制备得到的栓剂临床应用疗效一般,对粘膜组织有较强的刺激性。以上现有技术2CN101455715A制备得到的栓剂临床应用对粘膜组织虽无刺激性,但是制成的栓剂成型性较差,夏季常温易融化,临床使用较困难。我们在以上现有技术1-2组方的基础上,通过大量的处方筛选和药效学实验摸索,对我公司产品“妇炎平栓”的处方进行二次开发,发现在原处方的基础上将“苦木、盐酸小檗碱”改为“白鲜皮、丁香叶”,并对组方各原料药用量进行调整,发现本发明中药配方制成的中成药,其临床药效学实验效果显著提高,制成的栓剂成型性良好,夏季常温栓剂形状无变化,对粘膜组织无任何刺激性,无任何毒副作用;我们按常规工艺制成栓剂。
发明内容
本发明的目的在于:提供疗效更为显著一种治疗妇科疾病的栓剂及其制备方法。其特点是,本发明治疗妇科疾病的栓剂各原料药的组成为:
苦参400g-600g 蛇床子300g-500g 白鲜皮150g-350g
丁香叶100g-300g 珍珠层粉3-6g 枯矾50g-150g
薄荷脑3g-6g 冰片8g-12g 硼酸50g-70g。
本发明治疗妇科疾病的栓剂各原料药优选的组成为:
苦参500g 蛇床子400g 白鲜皮240g
丁香叶200g 珍珠层粉5g 枯矾100g
薄荷脑4g 冰片10g 硼酸60g。
本发明治疗妇科疾病的栓剂具体制备方法如下:
以上九味,取珍珠层粉、枯矾、冰片、薄荷脑、硼酸研成细粉,过筛,备用;另取蛇床子200g,粉碎成细粉,过筛,备用;取白鲜皮、丁香叶、苦参及剩余200g蛇床子加6倍量60%乙醇加热回流提取二次,每次2小时,滤过,合并滤液,在-0.08MPa 60~70℃条件下减压回收乙醇,浓缩至60℃测得相对密度为1.18~1.20的清膏,干燥,研成细粉,加入上述细粉,混合均匀,过筛;将混合脂肪酸甘油酯加热使熔化,滤过,于40~50℃保温,加入上述混合均匀的细粉,混匀,制成1000粒,即得栓剂。
本发明有益效果:现有技术检索:1、中国专利公报2005年1月5日公开了名称为“妇炎平栓及制备方法”公开号为CN1559577A的专利申请,此发明原料药的组成为:苦参500g、珍珠层粉5g、盐酸小檗碱40g、苦木400g、冰片10g、硼酸60g、蛇床子400g、薄荷脑4g、枯矾100g。2、中国专利公报2009年6月17日公开了名称为“一种用于治疗妇科疾病的栓剂及其制备方法”公开号为CN101455715A的专利申请,此发明原料药的组成为:苦参500g、珍珠层粉5g、枯矾100g、苦木400g、蛇床子400g、盐酸小檗碱40g、薄荷脑4g、冰片10g、硼酸60g、沙棘籽油250ml。发明人经多年研究发现:以上现有技术1CN1559577A制备得到的栓剂临床应用疗效一般,对粘膜组织有较强的刺激性。以上现有技术2CN101455715A制备得到的栓剂临床应用对粘膜组织虽无刺激性,但是制成的栓剂成型性较差,夏季常温易融化,临床使用较困难。我们在以上现有技术1-2组方的基础上,通过大量的处方筛选和药效学实验摸索,对我公司产品“妇炎平栓”的处方进行二次开发,发现在原处方的基础上将“苦木、盐酸小檗碱”改为“白鲜皮、丁香叶”,并对组方各原料药用量进行调整,发现本发明中药配方制成的中成药,其临床药效学实验效果显著提高,制成的栓剂成型性良好,夏季常温栓剂形状无变化,对粘膜组织无任何刺激性,无任何毒副作用;我们按常规工艺制成栓剂。本发明治疗妇科疾病的栓剂具有清热解毒、燥湿止带、杀虫止痒的功效;主要用于治疗湿热下注、带脉失约、赤白带下、阴痒阴肿,以及滴虫、霉菌、细菌引起的阴道炎、外阴炎等。本发明栓剂的用途是在治疗湿热下注、带脉失约、赤白带下、阴痒阴肿,以及滴虫、霉菌、细菌引起的阴道炎、外阴炎等药物中的应用。
药效学试验:
本发明中药组合物与最接近的现有技术相比,药效学试验效果显著提高。
最接近的现有技术:
1、中国专利公报2005年1月5日公开了名称为“妇炎平栓及制备方法”公开号为CN1559577A的专利申请,此发明原料药的组成为:苦参500g、珍珠层粉5g、盐酸小檗碱40g、苦木400g、冰片10g、硼酸60g、蛇床子400g、薄荷脑4g、枯矾100g。
主要药效学试验证明:
本发明各原料药重量配比“苦参500g、蛇床子400g、白鲜皮240g、丁香叶200g、珍珠层粉5g、枯矾100g、薄荷脑4g、冰片10g、硼酸60g。”同对比文件1(CN1559577A)重量配比组:“苦参500g、珍珠层粉5g、盐酸小檗碱40g、苦木400g、冰片10g、硼酸60g、蛇床子400g、薄荷脑4g、枯矾100g。”相比,药效学试验结果有显著提高。主要药效学试验如下:
(一)实验药物的制备:
1、原料:
本发明栓剂组:按照本发明说明书实施例1的方法制得,具体如下:
组方配比:
苦参500g 蛇床子400g 白鲜皮240g
丁香叶200g 珍珠层粉5g 枯矾100g
薄荷脑4g 冰片10g 硼酸60g;
制备方法:
以上九味,取珍珠层粉、枯矾、冰片、薄荷脑、硼酸研成细粉,过筛,备用;另取蛇床子200g,粉碎成细粉,过筛,备用;取白鲜皮、丁香叶、苦参及剩余200g蛇床子加6倍量60%乙醇加热回流提取二次,每次2小时,滤过,合并滤液,在-0.08MPa 60~70℃条件下减压回收乙醇,浓缩至60℃测得相对密度为1.18~1.20的清膏,干燥,研成细粉,加入上述细粉,混合均匀,过筛;将混合脂肪酸甘油酯加热使熔化,滤过,于40~50℃保温,加入上述混合均匀的细粉,混匀,制成1000粒,即得栓剂。
a组:按照现有技术对比文件1(CN1559577A说明书第2页第1-2行)的组方及本发明专利申请的工艺制备,具体如下:
组方配比:
苦参500g 珍珠层粉5g 盐酸小檗碱40g
苦木400g 冰片10g 硼酸60g
蛇床子400g 薄荷脑4g 枯矾100g;
以上九味,取珍珠层粉、盐酸小檗碱、枯矾、冰片、薄荷脑、硼酸研成细粉,过筛,备用;另取蛇床子200g,粉碎成细粉,过筛,备用;取苦木、苦参及剩余200g蛇床子加6倍量60%乙醇加热回流提取二次,每次2小时,滤过,合并滤液,在-0.08MPa 60~70℃条件下减压回收乙醇,浓缩至60℃测得相对密度为1.18~1.20的清膏,干燥,研成细粉,加入上述细粉,混合均匀,过筛;将混合脂肪酸甘油酯加热使熔化,滤过,于40~50℃保温,加入上述混合均匀的细粉,混匀,制成1000粒,即得栓剂。
(二)药效学实验过程:
实验目的:通过对本发明栓剂组和a组的抗炎、镇痛、止痒、解热和改善微循环等作用的药理实验研究,将本发明栓剂组与a组进行对比,观察其药理作用的强弱。
试验方法:本发明栓剂组和a组对小鼠腹腔毛细血管通透性的影响;对小鼠尾根加压所致疼痛的影响;对右旋糖酐引起小鼠瘙痒的影响;对大鼠实验性发热的影响;对小鼠耳廓微循环的影响。
一、对小鼠腹腔毛细血管通透性的影响
实验材料
1、动物:昆明种雌性小鼠,体重25~29g。
2、药物:本发明栓剂组和a组两个处方组。药物在实验前制备成所需浓度的栓剂,阴道给药。
实验方法
昆明种雌性小鼠30只,体重25~29g,随机分成3组,每组10只。对照组阴道给等量的基质;本发明栓剂组和a组分别阴道给药均为0.84g/kg,采用2次阴道给药,2次给药间隔时间为1h,末次阴道给药2h后,各组小鼠尾静脉注射0.5%伊文思蓝生理盐水溶液0.1ml/10g体重,随即腹腔注射0.6%的冰醋酸生理盐水0.2ml/只,20min后处死小鼠,剪开腹部皮肤肌肉,用6ml生理盐水分数次洗涤腹腔,吸管吸出洗涤液,合并后加入生理盐水至10ml,离心后取上清液于波长590nm处比色,测定吸光度值。实验结果:见表1
表1对小鼠腹腔毛细血管通透性的影响
与对照组相比*P<0.05,**P<0.01;与本发明栓剂组比△P<0.05。
结果表明:本发明栓剂组和a组均能明显减轻小鼠腹腔毛细血管的渗透性,本发明栓剂组与对照组相比有极显著性差异(P<0.01);a组与对照组相比有显著性差异(P<0.05);a组与本发明栓剂组相比有显著性差异(P<0.05)。可见,本发明栓剂组比a组的抗炎作用强。二、对小鼠尾根加压所致疼痛的影响
实验材料
1、动物:昆明种雌性小鼠,体重25~29g。
2、药物:本发明栓剂组和a组两个处方组。药物在实验前制备成所需浓度的栓剂,阴道给药。
实验方法
采用小鼠尾根压痛法,在离小鼠尾根1cm处,作为压痛点,用压痛仪测定痛阈值,以小鼠因尾部受压疼痛嘶叫为准,筛选痛阈值在10~45g内的昆明种雌性小鼠30只,体重25~29g,随机分为3组,每组10只。对照组阴道给等量的基质;本发明栓剂组和a组分别阴道给药均为0.84g/kg,采用2次阴道给药,2次给药间隔时间为1h,末次阴道给药2h后,测定痛阈值。实验结果:见表2
表2对小鼠尾根加压所致疼痛的影响
与对照组相比*P<0.05,**P<0.01;与本发明栓剂组比△P<0.05。
结果表明:本发明栓剂组和a组均可使小鼠尾根加压所致的痛阈值升高,本发明栓剂组与对照组相比有极显著性差异(P<0.01);a组与对照组相比有显著性差异(P<0.05);a组与本发明栓剂组相比有显著性差异(P<0.05)。可见,本发明栓剂组比a组的镇痛作用强。三、对右旋糖酐引起小鼠瘙痒的影响
实验材料
1、动物:昆明种雌性小鼠,体重25~29g。
2、药物:本发明栓剂组和a组两个处方组。药物在实验前制备成所需浓度的栓剂,阴道给药。
实验方法
昆明种雌性小鼠30只,体重25~29g,随机分成3组,每组10只。对照组阴道给等量的基质;本发明栓剂组和a组分别阴道给药均为0.84g/kg,采用2次阴道给药,2次给药间隔时间为1h,末次阴道给药2h后,尾静脉注射0.025%右旋糖酐0.05ml/10g可诱发阵发性瘙痒症状,表现为前爪搔头部,后爪搔躯干,咀咬身体各部,记录小鼠尾静脉注射右旋糖酐后0.5h内出现瘙痒持续的时间。实验结果:见表3
表3对右旋糖酐引起小鼠瘙痒的影响
与对照组相比*P<0.05,**P<0.01;与本发明栓剂组比△P<0.05。
结果表明:本发明栓剂组和a组能显著减少右旋糖酐诱发小鼠瘙痒症状的持续时间,本发明栓剂组与对照组相比有极显著性差异(P<0.01);a组与对照组相比有显著性差异(P<
0.05);a组与本发明栓剂组相比有显著性差异(P<0.05)。可见,本发明栓剂组比a组的止痒作用强。
四、对大鼠实验性发热的影响
实验材料
1、动物:Wistar雌性大鼠,体重180~220g。
2、药物:本发明栓剂组和a组两个处方组。药物在实验前制备成所需浓度的栓剂,阴道给药。
实验方法
Wistar雌性大鼠30只,体重180~220g,随机分成3组,每组10只。测量大鼠正常肛温2次,间隔0.5h测1次,连续两次测定体温相差应不大于0.2℃,取平均值为正常体温。各组大鼠皮下注射三联菌(伤寒、副伤寒甲、乙菌苗)3ml/kg,注射2h后,采用1次阴道给药,对照组阴道给等量的基质;本发明栓剂组和a组分别阴道给药均为0.42g/kg,阴道给药2h后,测量各组大鼠的体温。实验结果:见表4
表4对大鼠实验性发热的影响
与对照组相比*P<0.05,**P<0.01;与本发明栓剂组比△P<0.05。
结果表明:本发明栓剂组和a组对三联菌苗所致的大鼠实验性发热有显著的降低作用,本发明栓剂组与对照组相比有极显著性差异(P<0.01);a组与对照组相比有显著性差异(P<0.05);a组与本发明栓剂组相比有显著性差异(P<0.05)。可见,本发明栓剂组比a组的解热作用强。
五、对小鼠耳廓微循环的影响
实验材料
1、动物:昆明种雌性小鼠,体重25~29g。
2、药物:本发明栓剂组和a组两个处方组。药物在实验前制备成所需浓度的栓剂,阴道给药。
实验方法
昆明种雌性小鼠30只,体重25~29g,随机分成3组,每组10只。对照组阴道给等量的基质;本发明栓剂组和a组分别阴道给药均为0.84g/kg,采用2次阴道给药,2次给药间隔时间为1h,末次阴道给药2h后,小鼠腹腔注射0.45%戊巴比妥钠0.1ml/10g,将小鼠腹部向下平放于光学显微镜载物台上,使小鼠耳廓平展,在其表面滴加少许液体石蜡,用显微镜观察药物对小鼠耳廓微循环的影响,测定其微血流的速度。实验结果:见表5
表5对小鼠耳廓微循环的影响
与对照组相比*P<0.05,**P<0.01;与本发明栓剂组比△P<0.05。
结果表明:本发明栓剂组和a组能显著增加小鼠耳廓微血流的速度,促进血液循环,本发明栓剂组与对照组相比有极显著性差异(P<0.01);a组与对照组相比有显著性差异(P<0.05);a组与本发明栓剂组相比有显著性差异(P<0.05)。可见,本发明栓剂组比a组的改善微循环作用强。
实验结果:本发明栓剂组和a组能明显减轻小鼠腹腔毛细血管的渗透性;可使小鼠尾根加压所致的痛阈值升高;显著减少右旋糖酐诱发小鼠瘙痒症状的持续时间;对三联菌苗所致的大鼠实验性发热有显著的降低作用;显著增加小鼠耳廓微血流的速度,促进血液循环。
结论:本发明栓剂组比a组的抗炎、镇痛、止痒、解热和改善微循环等药理作用强,因此,本发明栓剂组比a组临床用于清热解毒、燥湿止带、杀虫止痒等治疗效果好,确定了本发明栓剂组的处方为本发明的处方。
具体实施方式
实施例1:本发明栓剂的制备:
组方配比:
苦参500g 蛇床子400g 白鲜皮240g
丁香叶200g 珍珠层粉5g 枯矾100g
薄荷脑4g 冰片10g 硼酸60g;
制备方法:
以上九味,取珍珠层粉、枯矾、冰片、薄荷脑、硼酸研成细粉,过筛,备用;另取蛇床子200g,粉碎成细粉,过筛,备用;取白鲜皮、丁香叶、苦参及剩余200g蛇床子加6倍量60%乙醇加热回流提取二次,每次2小时,滤过,合并滤液,在-0.08MPa 60~70℃条件下减压回收乙醇,浓缩至60℃测得相对密度为1.18~1.20的清膏,干燥,研成细粉,加入上述细粉,混合均匀,过筛;将混合脂肪酸甘油酯加热使熔化,滤过,于40~50℃保温,加入上述混合均匀的细粉,混匀,制成1000粒,即得栓剂。
实施例2:本发明栓剂的制备:
组方配比:
苦参400g 蛇床子300g 白鲜皮150g
丁香叶100g 珍珠层粉3 枯矾50g
薄荷脑3g 冰片8g 硼酸50g;
制备方法:
以上九味,取珍珠层粉、枯矾、冰片、薄荷脑、硼酸研成细粉,过筛,备用;另取蛇床子200g,粉碎成细粉,过筛,备用;取白鲜皮、丁香叶、苦参及剩余200g蛇床子加6倍量60%乙醇加热回流提取二次,每次2小时,滤过,合并滤液,在-0.08MPa 60~70℃条件下减压回收乙醇,浓缩至60℃测得相对密度为1.18~1.20的清膏,干燥,研成细粉,加入上述细粉,混合均匀,过筛;将混合脂肪酸甘油酯加热使熔化,滤过,于40~50℃保温,加入上述混合均匀的细粉,混匀,制成1000粒,即得栓剂。
实施例3:本发明栓剂的制备:
组方配比:
苦参600g 蛇床子500g 白鲜皮350g
丁香叶300g 珍珠层粉6g 枯矾150g
薄荷脑6g 冰片12g 硼酸70g;
制备方法:
以上九味,取珍珠层粉、枯矾、冰片、薄荷脑、硼酸研成细粉,过筛,备用;另取蛇床子200g,粉碎成细粉,过筛,备用;取白鲜皮、丁香叶、苦参及剩余200g蛇床子加6倍量60%乙醇加热回流提取二次,每次2小时,滤过,合并滤液,在-0.08MPa 60~70℃条件下减压回收乙醇,浓缩至60℃测得相对密度为1.18~1.20的清膏,干燥,研成细粉,加入上述细粉,混合均匀,过筛;将混合脂肪酸甘油酯加热使熔化,滤过,于40~50℃保温,加入上述混合均匀的细粉,混匀,制成1000粒,即得栓剂。
Claims (4)
1.一种治疗妇科疾病的栓剂,其特征在于所述栓剂的原料药组成为:
苦参400g-600g蛇床子300g-500g白鲜皮150g-350g
丁香叶100g-300g珍珠层粉3-6g枯矾50g-150g
薄荷脑3g-6g冰片8g-12g硼酸50g-70g。
2.根据权利要求1所述的栓剂,其特征在于所述栓剂优选的原料药组成为:
苦参500g蛇床子400g白鲜皮240g
丁香叶200g珍珠层粉5g枯矾100g
薄荷脑4g冰片10g硼酸60g。
3.根据权利要求1或2所述栓剂的制备方法,其特征在于:
以上九味,取珍珠层粉、枯矾、冰片、薄荷脑、硼酸研成细粉,过筛,备用;另取蛇床子200g,粉碎成细粉,过筛,备用;取白鲜皮、丁香叶、苦参及剩余200g蛇床子加6倍量60%乙醇加热回流提取二次,每次2小时,滤过,合并滤液,在-0.08MPa 60~70℃条件下减压回收乙醇,浓缩至60℃测得相对密度为1.18~1.20的清膏,干燥,研成细粉,加入上述细粉,混合均匀,过筛;将混合脂肪酸甘油酯加热使熔化,滤过,于40~50℃保温,加入上述混合均匀的细粉,混匀,制成1000粒,即得栓剂。
4.根据权利要求1-2任意一项栓剂或权利要求3所述栓剂的制备方法制备得到的栓剂在制备治疗湿热下注、带脉失约、赤白带下、阴痒阴肿,以及滴虫、霉菌、细菌引起的阴道炎、外阴炎等药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311741727.0A CN117482144A (zh) | 2023-12-18 | 2023-12-18 | 一种治疗妇科疾病的栓剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311741727.0A CN117482144A (zh) | 2023-12-18 | 2023-12-18 | 一种治疗妇科疾病的栓剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117482144A true CN117482144A (zh) | 2024-02-02 |
Family
ID=89683169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311741727.0A Pending CN117482144A (zh) | 2023-12-18 | 2023-12-18 | 一种治疗妇科疾病的栓剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117482144A (zh) |
-
2023
- 2023-12-18 CN CN202311741727.0A patent/CN117482144A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103520572B (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN1857690A (zh) | 妇科病制剂及新的制备方法 | |
CN107412430A (zh) | 一种玄参水提物及其应用 | |
CN100389794C (zh) | 一种治疗慢性肾功能衰竭的肾康栓及其制备工艺 | |
CN102631526B (zh) | 一种用于治疗糖尿病的中药组合物 | |
CN103272092A (zh) | 一种藿香正气外用制剂及其制备方法与用途 | |
CN103405620B (zh) | 一种治疗脂溢性脱发及斑秃的中药制剂及其制备方法 | |
CN117482144A (zh) | 一种治疗妇科疾病的栓剂及其制备方法 | |
CN101120977B (zh) | 一种治疗肿瘤的药物 | |
CN100355416C (zh) | 桂枝茯苓分散片及其制造方法 | |
CN1927324A (zh) | 用于治疗妇女月经不调中药制剂的制备方法 | |
CN1237985C (zh) | 治疗肿瘤的中药注射制剂及其制作方法 | |
CN101371905A (zh) | 一种治疗咽喉疾病的中药含片 | |
CN105998697A (zh) | 一种治疗食道癌的药物组合物 | |
CN101375955B (zh) | 一种用于治疗不射精症的通精制剂及其制备方法 | |
CN100457147C (zh) | 一种治疗妇女更年期综合征的中药组合物及制备方法 | |
CN1943755A (zh) | 一种治疗高血压的中药组合物及其制备方法 | |
CN1836703A (zh) | 一种治疗急性尿路感染的药物及其制备方法 | |
CN115300554B (zh) | 一种活血通络的中药制剂及其制备方法 | |
CN1186052C (zh) | 一种治疗盆腔炎的药物及其药物制剂和制备方法 | |
CN118286310B (zh) | 蕤仁或其提取物、组合物在治疗和/或预防肝损伤中的应用 | |
CN111281911B (zh) | 一种药物组合物及其制备方法和治疗子宫内膜异位的用途 | |
CN103055192B (zh) | 一种妇炎康复咀嚼片 | |
CN1242793C (zh) | 治疗妇科疾病的中药及其制备方法 | |
CN109745401B (zh) | 一种中药组合物的新用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |